Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly.
Sabina RuizJoan GilBetina BiagettiEva VenegasRosa CámaraRogelio Garcia-CentenoMaría-Ángeles GálvezAntonio PicóSilvia MaraverInmaculada GonzálezPablo AbellánPablo TrincadoMayte HerreraPilar OlveraGemma XifraIgnacio BernabéuGuillermo Serra-SolerSharona AzrielLourdes GarcíaDavide CarvalhoMireia JordàElena ValassiJosep PuigManel Puig-DomingoPublished in: Clinical endocrinology (2023)
T2-signal hyperintensity was more frequently observed in pasireotide treated patients. Almost 60% of SRLs resistant patients showed a complete normalization of IGF-I after 1 year of pasireotide treatment, regardless of the MRI signal. There was also no difference in the percentage tumour shrinkage over basal residual volume between the two groups.